Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX)

Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company focused on decoding biology to improve lives. The company has built an integrated drug discovery and development platform called the Recursion Operating System (OS). This platform combines large scale biological data generation, artificial intelligence driven chemistry design, and clinical development tools to move ideas from the lab to the clinic. By using automation and AI, Recursion aims to reduce the time and cost traditionally associated with bringing new medicines to patients. The OS works across three stages: first it generates detailed cellular images and molecular data, then it uses those data to design potential drug molecules, and finally it supports the planning and execution of clinical studies. This end to end approach allows the company to test many hypotheses quickly and to prioritize the most promising candidates for further development.

Recursion generates revenue primarily through strategic collaborations with pharmaceutical partners. The company receives upfront cash payments, milestone payments as programs advance, and is eligible for tiered royalties on future product sales. To date it has secured over five hundred million dollars in upfront and milestone payments from collaborations with Roche and Genentech, Sanofi, Bayer and Merck KGaA. Specific agreements include an upfront payment of one hundred fifty million dollars from Roche and Genentech, an upfront payment of one hundred million dollars from Sanofi, and an upfront payment of twenty million dollars from Merck KGaA. These partnerships also provide the potential for more than twenty billion dollars in additional milestones before royalties are paid. Recursion does not currently sell commercial products, so its revenue comes exclusively from these partnership activities.

Recursion occupies a distinctive place in the drug discovery industry as a technology driven biotech firm. Its main competitors include other TechBio companies such as Relay Therapeutics, Isomorphic Labs, Schrödinger and AbCellera, as well as large pharmaceutical firms that are increasingly adopting artificial intelligence in their research. The company’s competitive advantage stems from its proprietary data set of over fifty petabytes, its in house supercomputer BioHive 2, and its bilingual teams that blend expertise in biology and data science. This infrastructure enables the platform to synthesize far fewer compounds per program, approximately three hundred thirty compared with the industry average of two thousand five hundred, while maintaining high quality candidates. In addition, the OS uses machine learning models that are continuously updated with new experimental data, which improves the accuracy of predictions about drug behavior. These factors give Recursion a potential edge in efficiency and success rates, helping it to advance programs with lower attrition than traditional methods.

The company’s customers are primarily large pharmaceutical and biotechnology firms with which it collaborates. Current partners include Roche and Genentech, Sanofi, Bayer and Merck KGaA. Through these relationships, Recursion provides data, chemistry and clinical development services that help partners identify and advance therapeutic candidates. The company does not have direct sales to patients or consumers at this stage of development. While the company’s ultimate goal is to deliver medicines to patients, its present revenue base consists of these corporate collaborators.